China Pharma (CPHI): Market Cap to Earnings and Growth Ratio

China Pharma Holdings (CPHI) is expanding its presence in China's pharmacy segment by increasing the production of psychoneurological generics. The growth company undervaluation metric on GURU.Markets reflects the asset's dynamics, where the 0.00 mark represents the latest data. However, revenues are primarily based on treatments for infections and gastrointestinal disorders, while operating profit is currently undergoing a stage of cyclical margin stabilization amid domestic demand.
Analytical breakdowns for China Pharma Holdings Inc. (CPHI)

Conservative capital demands a transparent correlation between market value and real business expansion. This P/E and growth balance indicator measures valuation fairness by comparing the P/E ratio with earnings growth rates, where a value below one indicates an undervalued asset. For China Pharma Holdings (CPHI), which optimizes costs through the outsourcing of production and marketing, this metric confirms the efficiency of the operating model relative to the market price.